AstraZeneca COVID-19 Vaccine Clinical Trials in Britain for Children Stopped Due to Blood Clot Issues

AstraZeneca COVID-19 Vaccine Questions Continue Despite Warranties

Britain and the vaccine’s developers have so far resisted any restriction on its use, saying there was no evidence of any link.

A vial of the AstraZeneca COVID-19 vaccine doses that many nations have secured through an agreement with the Serum Institute of India in partnership with Verity Pharma, Wednesday, March 3, 2021, at a facility in Milton, Ontario. Image Credit: Carlos Osorio / Pool Photo via AP

A British AstraZeneca trial coronavirus The vaccine in children has been stopped, Oxford University said Tuesday, as global regulators rush to assess its possible link to rare blood clots in adults. The university, which helped develop the conflicting vaccine, said in a statement that there were “no safety concerns” in the trial, but acknowledged fears about a possible link to clots, saying it was waiting for additional data from the Drug Regulator. and Sanitary Products of Great Britain. Agency (MHRA) before restarting the study.

“Parents and children should continue to attend all scheduled visits and can contact the testing sites if they have any questions,” he added.

It is the latest drama to hit AstraZeneca, which has been embroiled in controversy over not delivering promised doses to the European Union and over the efficacy and safety profile of the jab.

The MHRA is one of many bodies around the world analyzing real-world data from the AstraZeneca launch to see if there is a definitive link between the puncture and a rare form of blood clot, after cases were initially reported in Norway. and continental Europe.

The MHRA reported over the weekend that there had been 30 cases of blood clotting, seven fatal, out of the 18 million doses administered in Britain.

The European Medicines Agency said Tuesday that it “has not yet reached a conclusion and the review is ongoing.”

EU Health Commissioner Stella Kyriakides later said the agency was expected to make its decision “on Wednesday night”, adding that it was in “close contact” with the EMA.

The statement came after EMA’s head of vaccine strategy Marco Cavaleri was quoted in Italian media as saying there was a “clear” connection and that the agency would announce it within hours.

“In my opinion, we can say it now, it is clear that there is a link with the vaccine,” Cavaleri told the Italian newspaper Il Messaggero in an interview. “But we still don’t know what causes this reaction.”

Germany and France have restricted the use of the vaccine to older people for fear that younger recipients have a potential higher risk of blood clots.

Britain and the vaccine’s developers have so far resisted any restriction on its use, saying there was no evidence of any link.

Adam Finn, a professor of pediatrics at Britain’s University of Bristol, said the benefits continued to outweigh the risks.

“We need to know more about the people affected and we need to understand exactly how the diseases arose,” he said.

“If you are currently offered a dose of the Oxford-AstraZeneca vaccine, your chances of staying alive and healthy will increase if you get the vaccine and decrease if you don’t,” he added.

Leave a Reply

Your email address will not be published. Required fields are marked *